(Albany, United States) As per DelveInsight’s assessment, globally, the Parkinson’s Disease Pipeline constitutes 140+ key companies continuously working towards developing 150+ Parkinson’s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Parkinson’s Disease Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Parkinson’s Disease clinical trials studies, Parkinson’s Disease NDA approvals (if any), and product development activities comprising the technology, Parkinson’s Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Parkinson’s Disease Pipeline treatment landscape of the report, click here @ Parkinson’s Disease Pipeline Outlook

 

Key Takeaways from the Parkinson’s Disease Pipeline Report

• DelveInsight’s Parkinson’s Disease Pipeline analysis depicts a robust space with 140+ active players working to develop 150+ pipeline treatment therapies.
• The leading Parkinson’s Disease Companies working in the market include Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others
• Promising Parkinson’s Disease Pipeline Therapies in the various stages of development include BIIB122, Rotigotine, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 20 mg, Methylprednisolone, Sirolimus, KM-819, VY-AADC02, Carbidopa/levodopa/entacapone, and others.
• On July 2023, Kainos Medicine Inc announced a study of phase 2 clinical trials for KM-819. The goal of this study is to test KM-819 in halting or slowing the progression of Parkinson’s disease. The study evaluates the safety and tolerability of multiple ascending doses of KM-819 in healthy older adults and participants with Parkinson’s disease.
• On May 2023, Prevail Therapeutics announced a study of phase 1 & 2 clinical trials for Methylprednisolone, and Sirolimus. Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson’s disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and clinical efficacy measures. Patients will continue to be followed for an additional 4 years to continue to monitor safety as well as selected biomarker and efficacy measures.
• On March 2023, Neurocrine Biosciences announced a study of phase 2 clinical trials for VY-AADC02. The objectives of this study are to assess the efficacy, safety and tolerability of VY-AADC02 in Patients with Parkinson’s Disease with Motor Fluctuations.

 

Parkinson’s Disease Overview

Parkinson’s disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine. Studies have shown that symptoms of Parkinson’s develop in patients with an 80 percent or greater loss of dopamine-producing cells in the substantia nigra.

 

To explore more information on the latest breakthroughs in the Parkinson’s Disease Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights

 

Parkinson’s Disease Emerging Drugs Profile

• Tavapadon: Cerevel Therapeutics
• IkT-148009: Inhibikase Therapeutics
• NLY01: Neuraly
• PT320: Peptron

 

Parkinson’s Disease Pipeline Therapeutics Assessment

There are approx. 140+ Parkinson’s Disease companies which are developing the therapies for Parkinson’s disease. The Parkinson’s Disease companies which have their Parkinson’s disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics.

 

Request a sample and discover the recent advances in Parkinson’s Disease Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights

 

Parkinson’s Disease Drugs and Companies

• Carbidopa/levodopa/entacapone: Novartis Pharmaceuticals
• VY-AADC02: Neurocrine Biosciences
• KM-819: FAScinate Therapeutics Inc.
• Methylprednisolone: Eli Lilly and Company

 

Parkinson’s Disease Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Parkinson’s Disease Therapeutics Market include-

Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.

 

Dive deep into rich insights for drugs for Parkinson’s Disease Pipeline, click here for Parkinson’s Disease Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights

 

Some of the Parkinson’s Disease Pipeline Report

• Coverage- Global
• Parkinson’s Disease Companies- Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
• Parkinson’s Disease Pipeline Therapies- BIIB122, Rotigotine, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 20 mg, Methylprednisolone, Sirolimus, KM-819, VY-AADC02, Carbidopa/levodopa/entacapone, and others.
• Parkinson’s Disease Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Parkinson’s Disease Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights

 

Table of Content

1. Introduction
2. Executive Summary
3. Parkinson’s Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Parkinson’s Disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tavapadon: Cerevel Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Prasinezumab : Roche
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MEDI1341: AstraZeneca
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Neural microtissues: Treefrog Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Parkinson’s Disease Key Companies
21. Parkinson’s Disease Key Products
22. Parkinson’s Disease- Unmet Needs
23. Parkinson’s Disease- Market Drivers and Barriers
24. Parkinson’s Disease- Future Perspectives and Conclusion
25. Parkinson’s Disease Analyst Views
26. Parkinson’s Disease Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services